News und Analysen
EQS-News: Gerresheimer Achieves A- Score in CDP Rating
EQS-News: Gerresheimer Achieves A- Score in CDP Rating
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures H1 2025: Earnings positive but below prior year – net sales stable – significant increase in order intake – forecast confirmed
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures H1 2025: Earnings positive but below prior year – net sales stable – significant increase in order intake – forecast confirmed
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up
EQS-News: Gerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
EQS-News: Gerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Sartorius completes acquisition of MatTek
EQS-News: Sartorius completes acquisition of MatTek
EQS-News: STRATEC ANNUAL GENERAL MEETING APPROVES DIVIDEND DISTRIBUTION OF € 0.60 PER SHARE
EQS-News: STRATEC ANNUAL GENERAL MEETING APPROVES DIVIDEND DISTRIBUTION OF € 0.60 PER SHARE
EQS-News: Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
EQS-News: Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
EQS-News: Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
EQS-News: Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
2 Dividend Stocks to Buy and Never Sell
There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.
EQS-Adhoc: Gerresheimer AG reacts to media reports
EQS-Adhoc: Gerresheimer AG reacts to media reports
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years
EQS-News: Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority
EQS-News: Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority
EQS-News: Evotec SE: Results of the Annual General Meeting 2025
EQS-News: Evotec SE: Results of the Annual General Meeting 2025
EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025
EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025
EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR
EQS-News: Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25
EQS-News: Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25
EQS-News: Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
EQS-News: Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
EQS-News: Drägerwerk AG & Co. KGaA: Dräger annual shareholders’ meeting approves dividend increase – Inclusion of the preferred shares in the TecDAX
EQS-News: Drägerwerk AG & Co. KGaA: Dräger annual shareholders’ meeting approves dividend increase – Inclusion of the preferred shares in the TecDAX